The Infectious Diseases Society of America (IDSA) guidelines, as of August 31, 2021, suggested the use of TCZ in hospitalized patients with progressive severe or critical COVID-19 who have elevated markers of inflammation such as C-reactive protein, serum ferritin, LDH, and IL-6. This evidence concerns the gene IL6 and COVID-19.